Allworth Financial LP Has $36,000 Position in ICU Medical, Inc. (NASDAQ:ICUI)

Allworth Financial LP raised its stake in ICU Medical, Inc. (NASDAQ:ICUI) by 100.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 200 shares of the medical instruments supplier’s stock after purchasing an additional 100 shares during the period. Allworth Financial LP’s holdings in ICU Medical were worth $36,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of ICUI. Silvercrest Asset Management Group LLC increased its holdings in shares of ICU Medical by 109.4% in the first quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier’s stock valued at $29,882,000 after purchasing an additional 145,485 shares during the last quarter. Mesirow Institutional Investment Management Inc. bought a new stake in ICU Medical during the first quarter worth about $15,425,000. Victory Capital Management Inc. lifted its position in ICU Medical by 2,966.3% during the second quarter. Victory Capital Management Inc. now owns 141,848 shares of the medical instruments supplier’s stock worth $16,844,000 after purchasing an additional 137,222 shares during the period. Millennium Management LLC lifted its position in ICU Medical by 327.8% during the second quarter. Millennium Management LLC now owns 136,070 shares of the medical instruments supplier’s stock worth $16,158,000 after purchasing an additional 104,264 shares during the period. Finally, Granite Investment Partners LLC bought a new stake in ICU Medical during the second quarter worth about $10,650,000. 96.10% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, VP Virginia Ruth Sanzone sold 2,050 shares of the stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $144.11, for a total value of $295,425.50. Following the transaction, the vice president now directly owns 4,482 shares in the company, valued at $645,901.02. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $16,320,691.72. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Virginia Ruth Sanzone sold 2,050 shares of the firm’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $144.11, for a total value of $295,425.50. Following the transaction, the vice president now owns 4,482 shares in the company, valued at approximately $645,901.02. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 40,552 shares of company stock worth $6,679,322 in the last ninety days. Corporate insiders own 6.70% of the company’s stock.

Wall Street Analyst Weigh In

ICUI has been the subject of a number of research reports. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a report on Thursday, October 10th. KeyCorp upped their price objective on ICU Medical from $147.00 to $198.00 and gave the company an “overweight” rating in a research note on Tuesday, October 15th. Raymond James upped their price objective on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research note on Thursday, September 12th. Jefferies Financial Group began coverage on ICU Medical in a research note on Monday, October 14th. They issued a “hold” rating and a $183.00 price objective for the company. Finally, StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a research note on Thursday, September 12th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, ICU Medical has a consensus rating of “Moderate Buy” and a consensus price target of $170.25.

ICU Medical Stock Performance

Shares of ICUI stock opened at $170.82 on Friday. The company has a market cap of $4.17 billion, a price-to-earnings ratio of -58.50 and a beta of 0.66. ICU Medical, Inc. has a 52 week low of $78.28 and a 52 week high of $188.53. The company has a quick ratio of 1.08, a current ratio of 2.41 and a debt-to-equity ratio of 0.76. The firm has a 50 day moving average of $174.09 and a 200-day moving average of $137.21.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported $1.56 EPS for the quarter, topping the consensus estimate of $1.00 by $0.56. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. The company had revenue of $596.50 million during the quarter, compared to the consensus estimate of $556.64 million. During the same quarter last year, the firm posted $1.58 EPS. The company’s quarterly revenue was up 8.6% on a year-over-year basis. On average, equities analysts forecast that ICU Medical, Inc. will post 3.81 earnings per share for the current year.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.